Integra LifeSciences (NASDAQ:IART – Get Free Report) released its quarterly earnings results on Wednesday. Integra LifeSciences updated its Q3 2026 guidance to 0.530-0.610 EPS and its FY 2026 guidance to 2.400-2.500 EPS. Hedge Funds Weigh In On Integra LifeSciencesKey Integra LifeSciences NewsHedge funds have recently modified their holdings of the stock. Integra LifeSciences Q2 Earnings Top EstimatesIntegra reported adjusted earnings of , exceeding the $0.48 analyst consensus and increasing from $0.45 a year earlier. Recommended StoriesReceive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.